Product Portfolio

Development Pipeline

Poziotinib

EGFR or HER2 Exon 20 Insertion Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Phase 2 Phase 3 Approved
HER2-Positive Metastatic Breast Cancer
Phase 1 Phase 2 Phase 3 Approved
HER2-Positive Advanced or Metastatic Breast Cancer in Combination With T-DM1
Phase 1 Phase 2 Phase 3 Approved

For more information click here.

ROLONTIS^® (eflapegrastim)

Chemotherapy-Induced Neutropenia (ADVANCE)
Phase 1 Phase 2 Phase 3 Approved
Chemotherapy-Induced Neutropenia (RECOVER)
Phase 1 Phase 2 Phase 3 Approved

For more information click here.

Apaziquone

Non-Muscle Invasive Bladder Cancer (CONQUER)
Phase 1 Phase 2 Phase 3 Approved

For more information click here.

Belinostat (Beleodaq®)

Front-Line Peripheral T-Cell Lymphoma (PTCL)
Phase 1 Phase 2 Phase 3 Approved

Pralatrexate (Folotyn®)

Front-Line Peripheral T-Cell Lymphoma (PTCL)
Phase 1 Phase 2 Phase 3 Approved

Developmental Trial Pivotal Trial